Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9; 12) translocation

Blood

Volumn 99, Issue 9, 2002, Pages 3465-3467

  O'Brien, Stephen G ^a,b,c,d   Vieira, Sara A D ^a,b,c,d   Connors, Samantha ^a,b,c,d   Bown, Nick ^a,b,c,d   Chang, James ^a,b,c,d   Capdeville, Renaud ^a,b,c,d   Melo, Junia V ^a,b,c,d  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLAST TRANSFORMATION; CASE REPORT; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; HUMAN; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0036566196     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.9.3465     Document Type: Article

References (16)

1. The fusion of TEL and ABL in human acute lymphoblastic leukaemia is a rare event
2. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia
3. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia
4. BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion
5. ETV6/ABL fusion is rare in Ph-negative chronic myeloid disorders
6. The second ETV6 allele is not necessarily deleted in acute leukemias with an ETV6/ABL fusion
7. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines
8. The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways
9. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
10. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopydmidine derivative
11. Inhibition of c-kit receptor tyrosine kinase activity by ST1571, a selective tyrosine kinase inhibitor
12. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
13. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
14. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
15. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders
16. Selection and characterization of BCR-ABL-positive cell lines with differential sensitivity to the tyrosine kinase inhibitor ST1571: Diverse mechanisms of resistance